Sarepta Therapeutics (SRPT) : 13 analysts are covering Sarepta Therapeutics (SRPT) and their average rating on the stock is 3, which is read as a Hold. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Sarepta Therapeutics (SRPT) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 3 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. 1 more analyst has given the stock a Sell recommendation. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Sarepta Therapeutics (SRPT) : 11 investment research analysts covering Sarepta Therapeutics (SRPT) have an average price target of $22.27 for the near short term. The highest target price given by the Brokerage Firm to the stock is $60 and the lowest target is $4 for the short term. Analysts expect the variance to be within $17.24 of the average price.
Also, Equity Analysts at the Brokerage Firm, Wedbush, reiterates their rating on the shares of Sarepta Therapeutics (NASDAQ:SRPT). Wedbush has a Outperform rating on the shares. As per the latest report, the brokerage house maintains the price target to $36 per share. The rating by the firm was issued on July 20, 2016.
Sarepta Therapeutics (NASDAQ:SRPT): The stock opened in the green at $31.07 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $31.1 and a low of $28.98 for the day. The stock did not find buyers even at the lows and closed at $30.02 recording a loss of -7.49%. 5,259,722 shares exchanged hands during the trading day. The stock had closed at $32.45 in the previous days trading.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.